Table 3.
Adjusted 3-year risk (PPV) of ≥CIN2 stratified by cytology, mRNA testing, and HPV genotyping
| Baseline cytology class | Risk ≥CIN2 (95% CI)a by single test group at baseline for: |
|||||
|---|---|---|---|---|---|---|
| mRNA− | mRNA+ | HPV16/18/31/33/45 DNA− | HPV16/18/31/33/45 DNA+ | HPV16 DNA− | HPV16 DNA+ | |
| Normal | 0.20 (0.07–0.33) | 0.55 (0.34–0.76) | 0.08 (−0.07–0.22) | 0.43 (0.28–0.58) | 0.27 (0.12–0.43) | 0.42 (0.22–0.63) |
| BMD | 0.43 (0.25–0.62) | 0.54 (0.32–0.75) | 0.38 (0.17–0.59) | 0.55 (0.36–0.73) | 0.39 (0.24–0.55) | 0.75 (0.48–1.02) |
| >BMD | 0.91 (0.80–1.03) | 0.90 (0.82–0.98) | 0.80 (0.60–1.00) | 0.93 (0.87–1.00) | 0.88 (0.77–0.99) | 0.93 (0.85–1.01) |
a
Risk estimates were corrected for lost to follow-up by means of Kaplan-Meier analysis. For these calculations, the absence of ≥CIN2 was defined as histology-proven CIN0/1 or a double-negative cytology and hrHPV DNA test result at the last follow-up visit. Similar data were obtained when only women with histology-confirmed CIN0/1 were considered to have ≥CIN2 (data not shown).